HealthQuill Breast cancer
British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the disease or the patient dying by 56% compared to the usual treatment.
Drugs Health Pharma

AstraZeneca’s pill to treat breast cancer cuts disease worsening by 56%

HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the.

Read More
US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.
Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European Union, the companies announced.
Drugs Medical Pharma

EU green lights AstraZeneca, Daiichi’s treatment for breast cancer

HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.

Read More
AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.
Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

Read More
Annual deaths caused by breast cancer globally will rise 68% to 1.1 million by 2050, according to a report from the International Agency for Research on Cancer, a specialised arm of the World Health Organization.
Drugs Health Pharma

Breast cancer death rates globally to rise 68% by 2050: WHO arm IARC warns

Annual deaths caused by breast cancer globally will rise 68% to 1.1 million by 2050, according to a report from the International Agency.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Health Medical

Hormonal contraceptives and breast cancer risk in BRCA1 carriers

HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.

Read More
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.
Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

Read More